| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 07/11/2002 | CA2433384A1 Neurotrophic tacrolimus analogs |
| 07/11/2002 | CA2432853A1 Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| 07/10/2002 | EP1220947A2 50 human secreted proteins |
| 07/10/2002 | EP1220929A1 Human ubiquitin protease |
| 07/10/2002 | EP1220906A1 Polynucleotides encoding members of the human b lymphocyte activation antigen b7 family and polypeptides encoded thereby |
| 07/10/2002 | EP1220900A2 Gene transfer vectors for treating autoimmune diseases and diseases with immunopathogenesis by therapy |
| 07/10/2002 | EP1220865A1 43 human secreted proteins |
| 07/10/2002 | EP1220852A1 Substituted diazepans |
| 07/10/2002 | EP1220845A1 Aryl-sulfonamide substituted benzimidazol derivatives and use of said as tryptase inhibitors |
| 07/10/2002 | CN1358195A Inhibitors of integrin alpha V beta 6 |
| 07/10/2002 | CN1358193A Steroid compounds with C17-alkyl side chain and aromatic A-ring for use in therapy |
| 07/10/2002 | CN1357322A Bioenergy muscle relexant |
| 07/09/2002 | US6417237 Macromolecular drug complexes and compositions containing the same |
| 07/09/2002 | US6417227 Methods of delivery of cetyl myristoleate |
| 07/09/2002 | US6417223 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses therof |
| 07/09/2002 | US6417219 Enzyme inhibitors and osteoarthritis |
| 07/09/2002 | US6417209 Heterocyclic ketone and thioester compounds and uses |
| 07/09/2002 | US6417189 Drugs with pyrazole ketone derivatives |
| 07/09/2002 | US6416991 Genetic engineered protein |
| 07/09/2002 | US6416975 Human glycine transporter type 2 |
| 07/04/2002 | WO2002052002A2 Immunomodulatory polynucleotides and methods of using the same |
| 07/04/2002 | WO2002051983A2 Novel compounds and compositions as cathepsin inhibitors |
| 07/04/2002 | WO2002051442A1 Concomitant drugs |
| 07/04/2002 | WO2002051418A1 Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists |
| 07/04/2002 | WO2002051397A1 Aniline derivatives or salts thereof and cytokine production inhibitors containing the same |
| 07/04/2002 | WO2002012346A8 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |
| 07/04/2002 | WO2001090148A8 Neurotransmitter transporters |
| 07/04/2002 | US20020086999 Certain quinoline derivatives |
| 07/04/2002 | US20020086996 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates |
| 07/04/2002 | US20020086875 Use of nicergoline in the treatment of spasticity |
| 07/04/2002 | US20020086871 Pharmaceutical composition for the treatment of CNS and other disorders |
| 07/04/2002 | US20020086832 Immunosuppressing a human after allogenic cell, tissue or organ transplantation by administering a caspase-8 inhibitor |
| 07/04/2002 | US20020086017 GA binding protein and neurite derived growth factors for use in the treatment of muscular dystrophy |
| 07/04/2002 | CA2436739A1 Combination agent |
| 07/04/2002 | CA2433520A1 Novel compounds and compositions as cathepsin inhibitors |
| 07/04/2002 | CA2430691A1 Immunomodulatory polynucleotides and methods of using the same |
| 07/03/2002 | EP1219622A2 Pharmaceutical compositions for CNS and other disorders |
| 07/03/2002 | EP1218509A2 Fibroblast growth factor-like polypeptides |
| 07/03/2002 | EP1218502A2 Nicotinic acetylcholine receptor : alpha10 subunit |
| 07/03/2002 | EP1218412A2 Human g-protein coupled receptor |
| 07/03/2002 | EP1218408A1 32 human secreted proteins |
| 07/03/2002 | EP1218403A2 Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery |
| 07/03/2002 | EP1218372A1 Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases |
| 07/03/2002 | EP1218369A1 INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
| 07/03/2002 | EP1218347A1 Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions |
| 07/03/2002 | EP1218013A2 Phospholipid prodrugs of anti-proliferative drugs |
| 07/03/2002 | EP1217963A1 Devices and methods for treating tissue |
| 07/03/2002 | EP1131062A4 Injectable propofol formulations |
| 07/03/2002 | CN1356987A Novel benzimidazole derivatives and pharmaceutical compsns. comprising these compounds |
| 07/02/2002 | US6414011 Central nervous system disorders |
| 07/02/2002 | US6413740 Nucleic acid which codes for muscle specific kinase c-terminal fragment of human agrin; diagnosis and treatment of muscle disorders and neuromusclar disorders |
| 06/27/2002 | WO2002050096A1 Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 06/27/2002 | WO2002050079A1 Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors |
| 06/27/2002 | WO2002050073A1 Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| 06/27/2002 | WO2002050066A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050065A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050057A1 Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders |
| 06/27/2002 | WO2002050033A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
| 06/27/2002 | WO2002050032A1 Naphthalene derivatives which bind to the ep4 receptor |
| 06/27/2002 | WO2002050031A1 Indole derivatives |
| 06/27/2002 | WO2002050028A2 Substituted benzoindoles as spla2 inhibitors |
| 06/27/2002 | WO2002050019A2 Diamines as modulators of chemokine receptor activity |
| 06/27/2002 | WO2002049993A2 High affinity small molecule c5a receptor modulators |
| 06/27/2002 | WO2002049625A2 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 06/27/2002 | US20020083477 Treating nerve damage; administer insulin like growth factor isoform to human, monitor response of damaged nerves |
| 06/27/2002 | US20020082388 Polypeptide for use in the treatment, diagnosis and prevention of cancer, nervous system and developmental disorders |
| 06/27/2002 | US20020082301 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| 06/27/2002 | US20020082283 Increasing the function of the N-methylaspartic acid (NMDA) receptor without the inherent side-effects associated with modulation of the glutamate binding site |
| 06/27/2002 | US20020082276 Quinoline derivatives as anti-inflammatory agents |
| 06/27/2002 | US20020082266 Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore |
| 06/27/2002 | US20020081607 Four disulfide core domain-containing (FDCD) polynucleotides, polypeptides, and antibodies |
| 06/27/2002 | US20020081290 Protein kinase homologs |
| 06/27/2002 | US20020081286 NRG-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 06/27/2002 | DE10137038A1 N-3,7 Substituted 1-Methylxanthine Derivates Displaying Inhibitory Activites on Type Five Phosphodiesterase N-Substituted 3,7-methylxanthine derivative Displaying 1 Inhibitory Activites on phosphodiesterase Type Five |
| 06/27/2002 | CA2714357A1 Mutations in neuronal gene sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 06/27/2002 | CA2432908A1 Diamines as modulators of chemokine receptor activity |
| 06/27/2002 | CA2432417A1 Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors |
| 06/27/2002 | CA2431891A1 Mutations in neuronal gene sodium-channel alpha 1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 06/27/2002 | CA2431023A1 Substituted benzoindoles as spla2 inhibitors |
| 06/27/2002 | CA2430918A1 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 06/26/2002 | EP1216309A2 Methods for targeting rna molecules |
| 06/26/2002 | EP1216297A2 Double transgenic animals as models for neurodegenerative disease |
| 06/26/2002 | EP1216257A1 Compounds for the treatment of ischemia |
| 06/26/2002 | EP1216241A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 06/26/2002 | EP1216049A2 Methods for treating muscular dystrophy with bone marrow cells |
| 06/26/2002 | EP1216024A1 Formulation for menopausal women |
| 06/26/2002 | EP0998288B1 Compositions containing capsaicin or capsaicin analogues and a local anesthetic |
| 06/26/2002 | EP0822812B1 Topical treatment and prevention of sagging subcutaneous muscle and overlying cutaneous tissue using acetylcholine precursors and catecholamines |
| 06/26/2002 | CN1355852A T cell receptor Vbeta-Dbeta-Jbeta sequence and methods for its detection |
| 06/26/2002 | CN1355021A Percutaneous medicine of strychnine (toxiferine or securinine) and salt thereof |
| 06/25/2002 | US6410790 Analgesics |
| 06/25/2002 | US6410592 Aminomethylcarboxylic acid derivatives |
| 06/25/2002 | US6410589 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease |
| 06/25/2002 | US6410555 Antiepileptic agents; headaches |
| 06/25/2002 | CA2220024C Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents |
| 06/20/2002 | WO2002048337A2 Secreted human proteins |
| 06/20/2002 | WO2002048145A1 Aminotriazolopyridiine derivatives as adenosine receptor ligands |
| 06/20/2002 | WO2002048117A1 Quinazolinone derivatives |
| 06/20/2002 | WO2002047719A2 Survical promoting ncam binding and ncam ligand biding compounds |
| 06/20/2002 | WO2002047708A2 Selective cox-2 inhibition from edible plant extracts |